Gemini Trial

This study will last for a period of up to 21 months. An 18-month screening period is planned for evaluating patients that are not currently experiencing flares of GPP, and will be re-evaluated every 6 months, or upon experiencing a flare. Once the patient is in flare, he or she may begin the screening period (Part 2) to continue the journey towards the study treatment day. During the treatment period, there are 8 visits over a 3-month period. Visits take approximately 1 to 3 hours each, except for the screening visit of part 2 that may take up to 4 hours.

Several blood samples will be collected on Day 1, Day 3, Week 1, Week 2, Week 4, Week 8 and Week 12. During the study visits, a physical evaluation of your GPP and overall health will be done by the study team. Non-invasive tape stripping to collect surface skin tissue samples will also be performed, and photography of your lesions will be conducted.

You may be offered to take part in another optional aspect of the trial, which includes additional blood draws and skin biopsies of your GPP lesions. For the biopsy portion, there will be a total of three punch biopsies.

At the end of the study, participants may be eligible to participate in the subsequent long term extension study, which may allow participants to receive the study treatment as a monthly injection under the skin, regardless of what they received during the first study. More information will be made available to you should you be interested.

For more information and to register to the study, please visit the study page:

https://gpptrial.com/